Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates

Diagn Microbiol Infect Dis. 2009 Sep;65(1):76-80. doi: 10.1016/j.diagmicrobio.2009.05.006.

Abstract

We evaluated the pharmacokinetic/pharmacodynamic parameters of 8 oral quinolones (ciprofloxacin, garenoxacin [GRNX], gatifloxacin, levofloxacin, moxifloxacin, prulifloxacin, sitafloxacin, and sparfloxacin) on 11 fluoroquinolone-resistant Streptococcus pneumoniae strains, screened from 780 strains isolated from various clinical sources in Japan. GRNX showed the highest area under the blood concentration time curve/MIC ratios, which exceeded the target values for bacterial eradication against all fluoroquinolone-resistant S. pneumoniae strains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Bacterial*
  • Humans
  • Japan
  • Microbial Sensitivity Tests
  • Microbial Viability
  • Pneumococcal Infections / microbiology*
  • Quinolones / pharmacokinetics*
  • Quinolones / pharmacology*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Quinolones